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Abstract
Aims In patients at high risk of heart failure following myocardial infarction (MI) as a result of residual left ventricular systolic
dysfunction (LVSD), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan may result in a greater attenuation of
adverse left ventricular (LV) remodelling than renin angiotensin aldosterone system inhibition alone, due to increased levels
of substrates for neprilysin with vasodilatory, anti-hypertrophic, anti-fibrotic, and sympatholytic effects.
Methods We designed a randomized, double-blinded, active-comparator trial to examine the effect of sacubitril/valsartan to
the current standard of care in reducing adverse LV remodelling in patients with asymptomatic LVSD following MI. Eligible pa-
tients were ≥3 months following MI, had an LV ejection fraction ≤40% as measured by echocardiography, were New York
Heart Association functional classification I, tolerant of an angiotensin-converting enzyme inhibitor or angiotensin receptor
blocker at equivalent dose of ramipril 2.5 mg twice daily or greater, and taking a beta-blocker unless contraindicated or intol-
erant. Patients were randomized to sacubitril/valsartan (target dose 97/103 mg twice daily) or valsartan (target dose 160 mg
twice daily). The primary endpoint will be change in LV end-systolic volume indexed for body surface area measured using car-
diac magnetic resonance imaging over 52 weeks from randomization. Secondary endpoints include other magnetic resonance
imaging-based metrics of LV remodelling, biomarkers associated with LV remodelling and neurohumoral activation, and
change in patient well-being assessed using a patient global assessment questionnaire.
Conclusions This trial will investigate the effect of neprilysin inhibition on LV remodelling and the neurohumoral actions of
sacubitril/valsartan in patients with asymptomatic LVSD following MI.
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Introduction
Routine use of coronary reperfusion therapy (initially with
thrombolysis and latterly with percutaneous intervention)
has reduced the degree of ventricular damage sustained at
the time of acute myocardial infarction (MI) and improved
survival.1 Despite this, the development of left ventricular
systolic dysfunction (LVSD) and subsequent heart failure
(HF) after acute infarction remains relatively common.2,3
The key mechanism underlying development of HF with re-
duced ejection fraction (HFrEF) following MI is the process
of pathological left ventricular (LV) remodelling.4 It is gener-
ally accepted that patients destined to develop HFrEF after
MI experience progressive LV enlargement and reduction in
LV ejection fraction (LVEF), developing over weeks, months,
years, or even decades after their acute coronary event. It
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is also accepted that such patients may remain symptomless
for a long period, despite significant LV enlargement and
LVSD. The prevention of adverse remodelling through phar-
macological inhibition of the maladaptive neurohumoral sys-
tem activation in patients at high risk of HFrEF following an
MI has been demonstrated to reduce the risk of developing
HFrEF and death.5 Indeed, four different neurohumoral an-
tagonists [angiotensin-converting enzyme (ACE) inhibitors or
angiotensin receptor blockers (ARBs), beta-blockers, and min-
eralocorticoid receptor antagonists] are life-saving in both pa-
tients at high risk of HF following MI and with established
chronic HFrEF.5–18 This is unsurprising given that, in many pa-
tients, HFrEF is part of the same physiological continuum ini-
tiated at the time of acute MI.
Not all neurohumoral systems activated in patients after
MI (or in HF) are harmful, and some endogenous neuro-
humoral systems may be protective. A-type natriuretic
peptide (ANP) and B-type natriuretic peptide (BNP) are
secreted by the heart in response to increased wall stress,
and these peptides promote vasodilation (reducing LV wall
stress), stimulate renal sodium and water excretion (i.e.
antagonizing the retention of salt and water characterizing
HF), and inhibit pathological growth, that is, hypertrophy
and fibrosis (key components of the adverse LV remodel-
ling that occurs after MI and in HFrEF).19 The augmenta-
tion of plasma levels of endogenous natriuretic peptides
can be achieved through inhibition of neprilysin, the en-
zyme responsible for the breakdown of natriuretic pep-
tides. In the Prospective Comparison of ARNI
(Angiotensin Receptor Neprilysin Inhibitor) with ACE inhib-
itor to Determine Impact on Global Mortality and Morbid-
ity in Heart Failure Trial (PARADIGM-HF), the addition of
neprilysin inhibition to blockade of the renin angiotensin
aldosterone system (RAAS) (using sacubitril/valsartan),
compared with RAAS blockade alone (using the
gold-standard ACE inhibitor enalapril), reduced the risk of
HF hospitalization and cardiovascular death in patients
with HFrEF.20 Given their vasodilatory, anti-hypertrophy,
anti-fibrotic, and sympatholytic effects, along with the clin-
ical benefits observed in patients with HFrEF, the augmen-
tation of natriuretic peptides and other substrates for
neprilysin (adrenomedullin, apelin, and glucagon-like pep-
tide-1, among others) with a neprilysin inhibitor presents
an attractive therapeutic proposal in patients with asymp-
tomatic LVSD after MI, in the hope of delaying or
preventing progression to HFrEF. Key to such a
therapeutico benefit would be attenuation of LV remodel-
ling over time.
To further explore this hypothesis, we have designed a
randomized-controlled trial comparing the angiotensin recep-
tor neprilysin inhibitor, sacubitril/valsartan, with the ARB,
valsartan, to provide information on the effect of neprilysin
inhibition on LV remodelling in patients at high risk after MI
as a result of residual LVSD.
Methods
Trial organization and sources of funding
The trial was conceived and designed by the Trial Steering
Committee. The trial was co-sponsored by the University of
Glasgow and the National Health Service Greater Glasgow
and Clyde health board. The trial protocol and any substantial
amendments to the protocol were approved by the East of
Scotland Research Ethics Committee.
This trial was funded by the British Heart Foundation (PG/
17/23/32850), and trial medication along with funding for
trial drug packaging, labelling, distribution, storage and
destruction was supplied by Novartis Pharmaceuticals UK
limited who had no input to the design. J. J. V. M. and
M. C. P. are supported by a British Heart Foundation Centre
of Research Excellence Grant (RE/18/6/34217).
Trial design
The trial is a multi-centre, prospective, randomized, double-
blind, active-comparator trial designed to evaluate the effect
of sacubitril/valsartan at a target dose of 97/103 mg twice
daily, compared with valsartan at a target dose of 160 mg
twice daily, on LV remodelling in patients with asymptomatic
LVSD following MI, considered to be at high risk of developing
HFrEF. The trial is registered as ClinicalTrials.gov Identifier:
NCT03552575.
Patient eligibility and consent
Consenting patients at least 3 months after acute MI (defined
according to the third universal definition of MI21) was eligi-
ble if they had an LVEF ≤40% as measured by transthoracic
echocardiography without any symptoms of HF (i.e. New York
Heart Association functional classification I), were taking a
minimum dose of ACE inhibitor/ARB (ramipril 2.5 mg BD or
equivalent, Supporting Information, Table S1), or were able
to tolerate such a dose, were treated with a beta-blocker, un-
less intolerant or contraindicated, and had a systolic blood
pressure ≥100mmHg. Patients were ineligible if they had per-
manent or persistent atrial fibrillation, an estimated glomeru-
lar filtration rate of <30 mL/min/1.73m2, and/or a serum
potassium level of >5.2 mmol/L. Full inclusion and exclusion
criteria are detailed in Table 1.
Echocardiography
Non-contrast transthoracic echocardiography was performed
in the left lateral decubitus position, and LVEF measured
using Simpson’s biplane method.22 Patients with insufficient
endocardial definition to allow accurate planimetry were
excluded.
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Trial procedures
Prior to randomization, patients had a series of baseline in-
vestigations including measurement of height, weight, a
physical examination, 12-lead electrocardiograph, spot urine
sample collection and blood sampling for clinical biochemis-
try, full blood count, and biomarker analysis. Following ran-
domization, study visits took place at 1, 2, 4, 5, 14, 26, 39,
and 52 weeks as detailed in Figure 1 and Supporting Informa-
tion, Table S2, with a particular focus on safety measure-
ments (blood pressure, potassium, and renal function
measurements) and the occurrence of any adverse events.
Cardiac magnetic resonance imaging
Cardiac magnetic resonance imaging (MRI) was performed
prior to randomization and at 12 months following
Table 1 Trial inclusion and exclusion criteria
Inclusion
criteria
● Acute myocardial infarction ≥3 months prior to randomization
● Left ventricular ejection ≤40% as measured by transthoracic echocardiography
● Ability to provide written, informed consent
● Age ≥18 years
● Tolerance of a minimum dose of ACE inhibitor/ARB (ramipril 2.5 mg twice daily or equivalent)
● Treatment with a beta-blocker unless not tolerated or contraindicated
Exclusion
criteria
● Contraindication to cardiac MRI (ferrous prosthesis, implantable cardiac device, or severe claustrophobia)
● Clinical (NYHA functional class ≥II) and/or radiological heart failure
● Symptomatic hypotension and/or systolic blood pressure <100 mmHg
● eGFR <30 mL/min/1.73m2 and/or serum potassium >5.2 mmol/L
● Persistent/permanent atrial fibrillation
● History of acute myocardial infarction within last 3 months
● History of hypersensitivity or allergy to ACE inhibitors/ARB
● History of angioedema
● Known hypersensitivity to the active study drug substances, contrast media, or any of the excipients
● Obesity (where body girth exceeds MRI scanner diameter)
● Pregnancy, planning pregnancy, or breast feeding
● Inability to give informed consent or comply with study protocol
● Evidence of hepatic disease as determined by any one of the following: AST or ALT values exceeding 2 × ULN at Visit 1,
history of hepatic encephalopathy, history of oesophageal varices, or history of portacaval shunt
● History of biliary cirrhosis and cholestasis
● Active treatment with cholestyramine or colestipol resins
● Active treatment with lithium or direct renin inhibitor
● Participation in another intervention study involving a drug or device within the past 90 days (co-enrolment in
observational studies is permitted)
ACE, angiotensin-converting enzyme; ALT, alanine aminotransferase; ARB, angiotensin receptor blocker; AST, aspartate aminotransferase;
eGFR, estimated glomerular filtration rate; MRI, magnetic resonance imaging; NYHA, New York Heart Association; ULN, upper limit of
normal.
Figure 1 Trial outline. Outline of the trial procedures. Eligible patients were randomized to either sacubitril/valsartan (target dose 97/103 mg twice
daily) or valsartan (target dose 160 mg twice daily) and matched placebo for 12 months. Cardiac magnetic resonance imaging (MRI) was performed
pre-randomization and at 12 months. Blood and urine collection for biomarker profiling was performed pre-randomization, at 6 and 12 months.
MI, myocardial infarction.
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randomization with a single 3 Tesla Siemens MAGNETOM
Prisma scanner at the Queen Elizabeth University Hospital
Glasgow Imaging Centre of Excellence. Images were ob-
tained with a phased-array chest coil, during breath-hold,
and gated to the electrocardiogram. The MRI protocol is
outlined in Figure 2, and detailed information is provided
in the Supporting Information. A single operator (R. T. C.),
accredited by the European Association of Cardiovascular
Imaging in cardiac MRI analysis with >5 years of experi-
ence, analysed all scans blinded to treatment assignment.
The baseline and 12 months of follow-up scans were
analysed in pairs to reduce intra-observer variability, using
the methods detailed in the Supporting Information and
in accordance with the Society for Cardiovascular Magnetic
Resonance and European Society of Cardiovascular Imaging
guidelines for reporting cardiovascular magnetic resonance
examinations.23,24 A random selection of scans (10%) was
analysed by a second operator blinded to treatment assign-
ment for assessment of inter-operator variability and qual-
ity assurance. All scans were reviewed by a third operator
(G. R.) for the purposes of a clinical report, review of
non-cardiac elements, and the presence of any incidental
findings.
Biomarkers
Venous blood and spot urine samples were collected at base-
line and at 6 and 12 months following randomization
(Figure 1). Samples were collected in chilled tubes and centri-
fuged immediately at 1500 g at 4°C for 10 min before
aliquoting and storage at 80°C. A protease inhibitor
(Aprotinin, Abcam, Cambridge, UK) was added to ethylenedi-
aminetetraacetic acid plasma to minimize degradation of la-
bile peptides such as ANP.
Patient global assessment of change
Patients completed a patient global assessment of change
questionnaire at the 12 months of visit. Details of the ques-
tionnaire and available responses are in the Supporting
Information.
Randomization and blinding
Following baseline measurements, participants were ran-
domly assigned to sacubitril/valsartan or valsartan in a 1:1
ratio. Patients were provided with two packs of tablets—
valsartan or matching placebo and sacubitril/valsartan or
matching placebo—and instructed to take one pill from each
pack (i.e. one active treatment and one placebo pill) twice
daily. Randomization was stratified by baseline left ventricu-
lar end-systolic volume index (LVESVI) measured using car-
diac MRI (≤45 mL/m2/>45 mL/m2) and by use of diuretics.
The randomization schedule was generated by a computer
using permuted blocks, with block lengths of 4 and 6. All par-
ticipants and trial staff were blind to treatment allocation.
Patients taking an angiotensin-converting enzyme inhibitor
at baseline
In order to minimize the risk of angioedema due to overlap-
ping ACE and neprilysin inhibition, all patients taking an ACE
inhibitor at baseline underwent a 36 h ‘washout’ period fol-
lowing randomization, prior to the first dose of study drug.
For the same reason, use of open-label ACE inhibitor or ARB
in addition to the randomized study drug was strictly
prohibited for the duration of the trial.
Dose adjustment
Three dose levels of study medication were available, with
planned stepwise up-titration (Figure 3). Study drug was
started at Dose Level 2 (sacubitril/valsartan 49 mg/51 mg
twice daily or valsartan 80 mg twice daily) and up-titrated
Figure 2 Cardiac magnetic resonance imaging protocol outline. Cardiac magnetic resonance imaging was performed pre-randomization and at
12 months following double-blind treatment with sacubitril/valsartan or valsartan. All scans were performed on a single, 3 Tesla Siemens MAGNETOM
Prisma scanner. Further details regarding the scan protocol are available in the Supporting Information.
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after 4 weeks to Dose Level 3 (sacubitril/valsartan 97 mg/
103 mg twice daily or valsartan 160 mg twice daily) if toler-
ated as assessed by clinical review (systolic blood pressure
and symptomatic hypotension) and laboratory evaluation
(potassium and renal function). Patients already on a high
dose of ACE inhibitor/ARB could start at Dose Level 3 at the
investigator’s discretion.
Alternatively, patients could be started at Dose Level 1
(sacubitril/valsartan 24 mg/26 mg twice daily), with a two-
step titration to target dose over Visits 3 and 4, if systolic
blood pressure at Visit 1 was 100 to 110 mmHg or if esti-
mated glomerular filtration rate was 30–60 mL/min/
1.73 m2. Down-titration was possible during follow-up, but
the goal was to maintain patients on Dose Level 3 for as much
of the trial as possible. Initial up-titration was only halted (or
dose subsequently decreased) because of safety or tolerabil-
ity concerns related to (i) symptomatic hypotension, (ii) a clin-
ically significant decline in renal function, or (iii)
hyperkalaemia (Figure 3).
Patients continued standard background therapy.
Development of heart failure and study drug/study discon-
tinuation during follow-up
Patients developing HF during follow-up were offered open-
label sacubitril/valsartan. Patients starting open-label
sacubitril/valsartan or withdrawing from study medication
(or study follow-up) ≥6 months after randomization were
asked to undergo an ‘end-of-study’ cardiac MRI examination
(patients withdrawing before 6 months were not asked to
have a second cardiac MRI as an effect of LV remodelling
was unlikely to be detected before that time point).
Trial endpoints
The primary and secondary endpoints will be measured as
change from baseline to 12 months of follow-up. The
between-treatment differences in these changes will be
analysed.
Primary endpoint
The primary endpoint is change in LV end-systolic volume,
measured using cardiac MRI, and indexed for body surface
area (LVESVI).
Secondary endpoints
The pre-specified secondary endpoints are as follows:
• change in N-terminal pro-B-type natriuretic peptide;
• change in high-sensitivity troponin I;
• change in other cardiac MRI-based metrics of LV
remodelling:
○ LV end-diastolic volume indexed for body surface area
○ left atrial volume indexed for body surface area
○ LVEF
○ LV mass index; and
• change in patient well-being, assessed using a patient
global assessment questionnaire.
Exploratory endpoints
The exploratory endpoints are as follows:
Figure 3 Trial drug initiation and up-titration. *Equivalent doses detailed in Supporting Information, Table S1. #Dose Level 1 could be considered for
patients with systolic blood pressure (SBP) ≥100 to 110 mmHg and/or moderate renal impairment [estimated glomerular filtration rate (eGFR) of
30–60 mL/min/1.73 m2] at time of randomization. AEs, adverse events.
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• change in biomarkers of LV remodelling: soluble suppres-
sion of tumourigenicity-2 (ST2), galectin-3, tissue inhibitor
matrix metalloproteinase-1 (TIMP-1), matrix
metallopeptidase-9 (MMP-9), Type III procollagen peptide,
growth differentiation factor-15 (GDF-15), and other
relevant biomarkers of interest;
• change in neurohormonal levels: BNP, mid-regional
pro-ANP, C-terminal ANP, C-type natriuretic peptide, mid-
regional pro-adrenomedullin, guanosine 3’,5’ cyclic
monophosphate (cGMP), endothelin-1, neprilysin antigen,
renin and aldosterone, and other relevant biomarkers of
interest; and
• change in extracellular volume fraction, LV global function
index, T1 relaxation time, and LV strain as measured using
cardiac MRI.
Statistical considerations
The study size was 100 patients, based on the calculation
that 45 patients in each treatment group provided >90%
power (α level = 0.05) to detect a difference of 6 mL/m2 in
LVESVI (standard deviation = 7.8 mL/m2),25 accounting for
a discontinuation rate of 10% (lost to follow-up, develop-
ment of HF, or death). A 6 mL/m2 difference in LVESVI was
selected as it is believed to represent a minimally important
difference.26,27
The primary analysis will include all patients randomized
with baseline and 12 months of outcome data on an inten-
tion-to-treat basis with no imputation for missing data. Each
efficacy outcome will be analysed using a regression analysis
model adjusted for the baseline value of the outcome in
question (e.g. LVESVI) and use of diuretic at baseline. MRI
outcomes will also include adjustment for the time from
baseline to follow-up MRI. Efficacy outcome measures will
be summarized at baseline, 12 months, and for the change
from baseline to 12 months, presented overall and by treat-
ment group. The effect of treatment will be presented with
95% confidence intervals and a two-sided P-value.
Discussion
Results from this trial will provide detailed insight into the ef-
fects of neprilysin inhibition, added to standard care, in pa-
tients at high risk of developing HF as a result of residual
LVSD following MI. It will be the first adequately powered,
randomized, and long-term examination of the effect of
sacubitril/valsartan on LV remodelling and the only compari-
son with valsartan, that is, the only study to ensure identical
background renin angiotensin blocking therapy in both ran-
domized treatment groups. The use of multi-parametric car-
diac MRI will provide high-fidelity information about the
effects of neprilysin inhibition on cardiac structure and func-
tion and, along with comprehensive biomarker profiling of
patients, will provide further understanding of the
mechanisms of action underlying the clinical benefits
observed with sacubitril/valsartan in patients with HFrEF.
The presence of LVSD and LV dilatation are powerful
predictors of the risk of developing HF following MI. Prior
to reperfusion therapy, the major therapeutic breakthrough
in MI was the demonstration that ACE inhibitors, given to
prevent adverse LV remodelling in high-risk patients, reduced
the likelihood of developing HF and the risk of death.5 These
benefits were seen in three seminal trials—Survival And Ven-
tricular Enlargement (SAVE, with captopril), Acute Infarction
Ramipril Efficacy, and TRAndolapril Cardiac Evaluation
Study.5,11,13 In the Valsartan in Acute Myocardial Infarction
Trial (VALIANT), the ARB valsartan was shown to be as effec-
tive as captopril used at the same dose as in SAVE, and the
ability of ACE inhibitors and ARB to attenuate adverse LV re-
modelling is believed to be related to the clinical benefits of
these treatments.14,28,29 Furthermore, in patients with HFrEF,
the clinical benefits of ACE inhibitors, ARB, beta-blockers, and
cardiac resynchronization therapy are, in part, related to ben-
eficial effects on adverse LV remodelling.30 Indeed, the effect
of HFrEF treatments on LV volumes has been shown to signif-
icantly correlate with a therapy’s effect on mortality in large
randomized-controlled trials.31
What evidence do we have for a reversal of LV remodelling
with neprilysin inhibition? A series of experimental models of
MI and HFrEF have reported positive effects of neprilysin in-
hibition on metrics of LV remodelling.32,33 The exogenous ad-
ministration of ANP has previously been reported to reduce
infarct size and increase LVEF in approximately 600 patients
with an acute ST-elevation MI.34 Similar findings have been
reported with the recombinant BNP nesiritide, and these
findings suggest that the augmentation of natriuretic pep-
tides (which is what neprilysin inhibition leads to) may have
a reverse-remodelling effect in patients with LVSD following
acute MI.35 Several observational studies have reported
favourable effects of sacubitril/valsartan on LV systolic func-
tion and volumes in patients with HFrEF (frequently with a
history of prior MI), but these studies are limited in their abil-
ity to draw conclusions given the inherent limitations of such
uncontrolled data.36,37 PARADIGM-HF did not include an
echocardiographic sub-study, and to date, two randomized-
controlled trials have reported on the effect of sacubitril/
valsartan on LV remodelling in HFrEF. The Pharmacological
Reduction of Functional, Ischemic Mitral Regurgitation trial
compared sacubitril/valsartan with valsartan in patients with
HF (defined as LVEF <50% with New York Heart Association
functional classification II/III symptoms) and significant func-
tional mitral regurgitation.38 Compared with valsartan, treat-
ment with sacubitril/valsartan for 12 months significantly
reduced both the degree of mitral regurgitation and LV
end-diastolic volume as measured by echocardiography. The
Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic
Stiffness in Patients With Mild to Moderate HF With Reduced
Ejection Fraction (EVALUATE-HF) reported no beneficial effect
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of sacubitril/valsartan on the primary endpoint of central aor-
tic stiffness.39 No between-treatment difference in the
pre-specified secondary endpoint of LVEF was observed;
however, sacubitril/valsartan, compared with enalapril, did
improve the other pre-specified secondary endpoints of LV
and left atrial volumes after 12 weeks of follow-up. The use
of cardiac MRI imaging in our trial differentiates it to those
reported earlier. Cardiac MRI is the gold-standard method
for measuring LV volumes with a superior spatial resolution
and reproducibility than echocardiography. Furthermore, car-
diac MRI has the additional feature of tissue characterization,
allowing quantification of myocardial scar and extracellular
volume fraction, which is of interest in this population given
the potential anti-fibrotic effects of sacubitril/valsartan.
There are also few data demonstrating the neurohumoral
effects of neprilysin inhibition potentially underlying the clin-
ical benefits of sacubitril/valsartan in patients with HFrEF. The
substrates for neprilysin are ubiquitous and include the natri-
uretic peptides, adrenomedullin, endothelin, angiotensin II,
substance P, bradykinin, vasoactive intestinal peptide, calcito-
nin gene-related peptide, and glucagon-like peptide-1, among
others. Following on from PARADIGM-HF, subsequent analy-
ses have reported only modest increases in BNP in contrast
to ANP, a finding that is perhaps not unsurprising given the
greater affinity neprilysin has for ANP relative to BNP.40,41
Biomarkers of pro-fibrotic processes (a key factor in the pro-
gression of adverse LV remodelling) have been reported to be
reduced with sacubitril/valsartan compared with enalapril42;
it is not clear, however, whether these findings reflect a di-
rect effect of neprilysin inhibition on pro-fibrotic signalling
or are simply an indirect effect of the reduction in LV wall
stress and myocardial injury as evidenced by the reductions
in the N-terminal pro-B-type natriuretic peptide and troponin
seen with sacubitril/valsartan.43 It therefore remains to be
seen which of the substrates for neprilysin (or which combi-
nations) play a key role in the mechanism of action of
neprilysin inhibition. Many of the peptides mentioned earlier
are unable to be measured in large, multi-centre, multi-
national randomized-controlled trials due to their instability
and difficulties in rapid measurement, as well as the need
for special assays for some. The design of the present trial
overcomes these hurdles, and we hope to provide novel in-
formation on the effect of neprilysin inhibition on these
biomarkers and the correlation with any remodelling effect.
Several other features of the trial design merit further
discussion. We recruited patients with asymptomatic LVSD
identified at least 3 months after MI to ensure resolution of
‘stunning’ (reversible LVSD). This will distinguish our study
from the Prospective ARNI vs. ACE Inhibitor Trial to Deter-
mIne Superiority in Reducing Heart Failure Events After MI
(PARADISE-MI), which is enrolling patients up to 7 days after
acute infarction and does not require all patients to have
LVSD.44 A further distinguishing feature is the choice of com-
parator agent; unlike PARADIGM-HF and PARADISE-MI that
used an ACE inhibitor (enalapril and ramipril, respectively),
in the present trial, the use of valsartan at the dose shown
to be as efficacious as captopril (target dose 50 mg three
times daily) in the VALIANT will allow us to precisely define
the effects of neprilysin inhibition per se without the uncer-
tainty about comparing renin angiotensin system blockade
with an ACE inhibitor, compared with an ARB. Our choice of
primary endpoint, LV end-systolic volume, has been shown
to be a major determinant of survival after MI, and improve-
ments in LV end-systolic volume are associated with im-
proved outcomes in high-risk patients following MI.28,29,45,46
We did not consider it ethical to carry out a trial like the
one we are conducting in patients with symptomatic HFrEF
as sacubitril/valsartan has already been shown to be defini-
tively superior to RAAS blockade alone in those patients.20
Conclusions
Despite advances in the management of acute MI, patients
remain at substantial risk of developing HF as a result of re-
sidual LVSD. Inhibition of neprilysin activity in combination
with RAAS blockade, using sacubitril/valsartan, has been
demonstrated to improve outcomes in patients with
established symptomatic HFrEF. However, the mechanisms
of action underlying these clinical benefits remain unclear.
They may, in part, be due to a reverse-remodelling effect of
neprilysin inhibition and increased levels of the vasoactive
substrates of the enzyme, including the natriuretic peptides,
among others. Results from this trial will provide comprehen-
sive information regarding the effects of neprilysin inhibition
on LV remodelling and the neurohumoral actions of
sacubitril/valsartan in patients at high risk of HF following MI.
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